Got 90 seconds? Then listen to Recce Pharmaceuticals Executive Director James Graham give us a run down of the company’s antibiotic research and impressive start to 2019.
Recce Pharmaceuticals (ASX:RCE) is a pharmaceutical company focused on the development and commercialisation of a new class of synthetic antibiotics.
The company’s lead drug, known as RECCE 327, has been developed for the treatment of blood infections and sepsis.
Stockhead spoke with Recce Pharmaceuticals Executive Director James Graham to give investors insights into the business.
Have a good idea for our next 90 Seconds With… segment? Email us at tv@stockhead.com.au.